Equities

Envoy Medical Inc

COCH:NAQ

Envoy Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.05
  • Today's Change-0.19 / -5.86%
  • Shares traded17.36k
  • 1 Year change-69.92%
  • Beta--
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Envoy Medical, Inc. is a hearing health company. The Company is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.

  • Revenue in USD (TTM)297.00k
  • Net income in USD-22.43m
  • Incorporated2020
  • Employees34.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nutriband Inc2.09m-5.49m53.20m13.00--6.67--25.51-0.6863-0.68630.26220.72670.24576.1515.94---64.63-55.21-72.05-66.7441.3433.32-263.05-315.870.854-82.630.0312--0.274153.43-22.35--65.57--
Milestone Scientific Inc9.48m-7.06m55.21m17.00--7.34--5.82-0.0948-0.09480.12650.09740.80250.775612.04557,570.60-60.13-55.48-80.86-74.7269.4263.97-74.93-88.941.80--0.0011--11.600.423320.41---7.99--
Apyx Medical Corp50.45m-22.81m55.43m252.00--2.74--1.10-0.6583-0.65831.460.58460.79141.774.49200,202.40-35.94-25.24-46.73-29.9763.7066.11-45.41-46.004.94-9.210.6207--17.6125.8219.28--7.99--
Alpha Pro Tech, Ltd.60.92m4.21m56.69m124.0013.490.894811.030.93060.35960.35965.225.420.89081.688.21491,250.006.1615.216.3316.0638.1940.236.9212.9315.31--0.000.00-1.215.6027.642.935.50--
InspireMD Inc6.48m-22.69m56.84m65.00--1.52--8.78-0.7594-0.75940.21081.500.20912.344.9799,646.16-73.26-60.59-86.14-72.9726.6520.46-350.35-334.787.41--0.00--20.0011.50-7.71--41.57--
Medinotec Inc3.05m-566.90k58.67m29.00--28.27--19.24-0.0483-0.04830.25980.17690.67122.0616.96105,130.70-12.48---13.23--53.56---18.59--8.571.440.4323---3.91---184.47------
Beyond Air Inc689.00k-66.70m60.13m98.00--2.23--87.27-2.13-2.130.02190.58670.0111.441.247,030.61-112.64-70.88-148.49-88.69-115.24---10,288.68-1,530.313.26--0.382-------29.27------
Monogram Technologies Inc365.00k-13.39m62.39m28.00------170.93-0.4414-0.44140.012--0.0316----13,035.71-115.81-119.26-226.52-257.400.00---3,669.37-5,045.60----0.00-------0.3964---15.97--
Envoy Medical Inc297.00k-22.43m63.50m34.00------213.82-2.21-2.210.0194-0.37820.04940.47372.368,735.29-381.38---2,885.46---118.18---7,718.86--0.8969-16.54----33.33---87.83------
Hyperfine Inc11.69m-41.93m64.81m131.00--0.8568--5.54-0.5858-0.58580.16331.050.11271.032.8089,251.91-40.40---43.95--42.39---358.59--8.26--0.00--61.90--39.54------
DIH Holding US Inc60.30m-1.77m64.87m--------1.08-0.0435-0.04351.49-0.8079----------------60.18---2.93--0.26561.50----12.15--80.41------
Pro-Dex Inc48.24m5.00m65.99m146.0013.882.1510.921.371.391.3913.448.980.97462.303.68330,438.3010.1115.4312.9418.8728.2533.1510.3714.922.16--0.27530.009.6215.4654.7232.380.8422--
Heartbeam Inc0.00-15.11m66.61m15.00--5.31-----0.6111-0.61110.000.47620.00----0.00-200.17---258.74--------------0.00-------12.94------
Asensus Surgical Inc8.72m-78.71m68.08m207.00--5.22--7.80-0.3065-0.30650.03390.04790.12711.7913.0942,144.93-114.63-71.10-146.89-79.04-52.04-71.39-902.25-1,207.710.689--0.00--21.02-18.67-3.80---6.14--
Vivos Inc18.00k-3.20m68.18m10.00--50.81--3,787.54-0.0087-0.00870.000050.00340.0127--3.13---225.38-202.25-235.64-552.77-33.3310.79-17,805.45-11,969.07----0.00---46.58---17.19------
Data as of May 21 2024. Currency figures normalised to Envoy Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

3.60%Per cent of shares held by top holders
HolderShares% Held
Lumyna Investments Ltd.as of 30 Sep 2022164.54k0.84%
HighTower Advisors LLCas of 31 Mar 2024164.32k0.84%
The Vanguard Group, Inc.as of 31 Mar 202494.60k0.48%
Geode Capital Management LLCas of 31 Mar 202489.98k0.46%
Polar Asset Management Partners, Inc.as of 31 Mar 202480.00k0.41%
SSgA Funds Management, Inc.as of 31 Mar 202435.07k0.18%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202431.54k0.16%
Weiss Asset Management LPas of 31 Mar 202420.00k0.10%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202414.04k0.07%
JPMorgan Alternative Asset Management, Inc.as of 31 Dec 202212.35k0.06%
More ▼
Data from 30 Sep 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.